Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer.

[1]  N. Sadato,et al.  The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. , 1999, Japanese journal of clinical oncology.

[2]  A. Alavi,et al.  Prognostic value of FDG PET imaging in malignant pleural mesothelioma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  R. Coleman,et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.

[4]  C. Cordon-Cardo,et al.  Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. , 1998, Cancer research.

[5]  H. Yagata,et al.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.

[6]  M Mazumdar,et al.  Clinical trials in relapsed prostate cancer: defining the target. , 1996, Journal of the National Cancer Institute.

[7]  J. Montie,et al.  Current prognostic factors for prostate carcinoma , 1996, Cancer.

[8]  P. Lipponen,et al.  A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. , 1996, Anticancer research.

[9]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[10]  G Jakse,et al.  Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.

[11]  K. McVary,et al.  Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate , 1995, Cancer.

[12]  H I Scher,et al.  Bone metastases: improving the therapeutic index. , 1994, Seminars in oncology.

[13]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  R. Lufkin,et al.  Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers , 1994 .

[15]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[16]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  G Di Chiro,et al.  Prediction of survival in glioma patients by means of positron emission tomography. , 1985, Journal of neurosurgery.

[18]  Susan M. Chang,et al.  18‐fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma , 1997, Cancer.